BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
5/20/2021 3:14:20 PM | Browse: 473 | Download: 1161
 |
Received |
|
2021-03-07 19:13 |
|
Peer-Review Started |
|
2021-03-07 19:19 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-29 14:51 |
|
Revised |
|
2021-03-30 11:20 |
|
Second Decision |
|
2021-04-29 09:21 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2021-04-29 11:35 |
|
Articles in Press |
|
2021-04-29 11:35 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-05-06 20:06 |
|
Typeset the Manuscript |
|
2021-05-19 01:18 |
|
Publish the Manuscript Online |
|
2021-05-20 15:14 |
| ISSN |
1948-5182 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Opinion Review |
| Article Title |
COVID-19 and the liver: What do we know so far?
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Prashant Nasa and George Alexander |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Prashant Nasa, MD, Chief Doctor, Critical Care Medicine, NMC Specialty Hospital, Amman Street, Al Nahda 2, Dubai 7832, United Arab Emirates. dr.prashantnasa@hotmail.com |
| Key Words |
COVID-19; Chronic liver disease; SARS-CoV-2; Severe acute respiratory syndrome coronavirus; Liver transplant; Liver and SARS-CoV-2 vaccines; SARS-CoV-2 induced liver injury |
| Core Tip |
Liver involvement in coronavirus disease 2019 (COVID-19) is either due to viral cytotoxicity or secondarily to systemic immune dysregulation. Patients with pre-existing liver disease are at higher risk of disease progression, morbidity, and mortality. Chronic liver disease with COVID-19 should be managed as per the standard guidelines, with education on hand hygiene, social distance, and face masks to reduce hospital admissions. There is no evidence that currently available vaccines for severe acute respiratory syndrome will have any complications different from other inactivated vaccines and are recommended for patients with pre-existing liver disease, hepatocellular carcinoma, or liver transplant recipients. |
| Publish Date |
2021-05-20 15:14 |
| Citation |
Nasa P, Alexander G. COVID-19 and the liver: What do we know so far? World J Hepatol 2021; 13(5): 522-532 |
| URL |
https://www.wjgnet.com/1948-5182/full/v13/i5/522.htm |
| DOI |
https://dx.doi.org/10.4254/wjh.v13.i5.522 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
